Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511372 | 0.94 | NPC1 (0.44) | NPC1RAB9AP2RX3LTA4HKCNH2 | |
| SCHEMBL4520509 | 0.91 | NPC1 (0.44) | NPC1RAB9ALTA4HKCNH2CYP1A2 | |
| SCHEMBL4518430 | 0.88 | NPC1 (0.43) | NPC1RAB9AP2RX3LTA4HCYP1A2 | |
| SCHEMBL4519186 | 0.88 | NPC1 (0.52) | NPC1RAB9ALTA4HKCNH2CYP1A2 | |
| SCHEMBL4714563 | 0.85 | PTGDR2 (0.41) | P2RX3PTGDR2CYP26A1LTA4HKCNH2 | |
| SCHEMBL4525186 | 0.84 | NPC1 (0.50) | NPC1RAB9ALTA4HKCNH2CYP1A2 | |
| SCHEMBL4790440 | 0.84 | ACACB (0.41) | NPC1RAB9ALTA4HKCNH2CYP1A2 | |
| SCHEMBL4519215 | 0.84 | ACACB (0.47) | NPC1RAB9AMAPTMEN1ALDH1A1 | |
| SCHEMBL4521582 | 0.83 | NPC1 (0.45) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4514304 | 0.83 | NPC1 (0.47) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996567-B1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC (US) | 2013-09-18 | — | — | EP | claimed |
| US-8207350-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBOTT LABORATORIES (US) | 2012-06-26 | — | — | US | claimed |
| US-20090048298-A1 | Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome | ABBOTT LABORATORIES (US) | 2009-02-19 | — | — | US | claimed |
| EP-1996567-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2008-12-03 | — | — | EP | claimed |
| US-20070219258-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES | 2007-09-20 | — | — | US | claimed |
| WO-2007095601-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | claimed |
| EP-1996567-B1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8207350-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBOTT LABORATORIES (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090048298-A1 | Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome | ABBOTT LABORATORIES (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1996567-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20070219258-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES | 2007-09-20 | — | — | US | disclosed |
| WO-2007095601-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219258-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | NPC1 771/4885RAB9A 3796/4885P2RX3 4683/4885 |
| US-20090048298-A1 | Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome | ACACA, ACACB, ACAT1 | NPC1 771/4885RAB9A 3796/4885P2RX3 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.